Logo image of BIAF

BIOAFFINITY TECHNOLOGIES INC (BIAF) Stock Overview

USA - NASDAQ:BIAF - US09076W1099 - Common Stock

3.41 USD
-0.88 (-20.51%)
Last: 9/25/2025, 5:06:09 PM
3.32 USD
-0.09 (-2.64%)
After Hours: 9/25/2025, 5:06:09 PM

BIAF Key Statistics, Chart & Performance

Key Statistics
52 Week High67.12
52 Week Low3.4
Market Cap97.08M
Shares28.47M
Float23.17M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.7
PEN/A
Fwd PEN/A
Earnings (Next)11-12 2025-11-12
IPO08-26 2022-08-26
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


BIAF short term performance overview.The bars show the price performance of BIAF in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

BIAF long term performance overview.The bars show the price performance of BIAF in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of BIAF is 3.41 USD. In the past month the price decreased by -54.3%. In the past year, price decreased by -94.5%.

BIOAFFINITY TECHNOLOGIES INC / BIAF Daily stock chart

BIAF Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.64 386.06B
AMGN AMGEN INC 12.43 145.99B
GILD GILEAD SCIENCES INC 14.34 137.72B
VRTX VERTEX PHARMACEUTICALS INC 22.54 97.91B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.93B
REGN REGENERON PHARMACEUTICALS 12.17 58.88B
ARGX ARGENX SE - ADR 76.71 43.52B
ONC BEONE MEDICINES LTD-ADR 5.75 39.08B
INSM INSMED INC N/A 28.66B
BNTX BIONTECH SE-ADR N/A 23.58B
NTRA NATERA INC N/A 22.46B
BIIB BIOGEN INC 8.47 19.89B

About BIAF

Company Profile

BIAF logo image bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The company is headquartered in San Antonio, Texas and currently employs 57 full-time employees. The company went IPO on 2022-08-26. The company develops noninvasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis developed by machine learning, a form of artificial intelligence (AI). The Company’s product, CyPath Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of the Company. CyPath Lung uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor.

Company Info

BIOAFFINITY TECHNOLOGIES INC

3300 Nacogdoches Road, Suite 216

San Antonio TEXAS US

Employees: 57

BIAF Company Website

BIAF Investor Relations

Phone: 12106985334

BIOAFFINITY TECHNOLOGIES INC / BIAF FAQ

What is the stock price of BIOAFFINITY TECHNOLOGIES INC today?

The current stock price of BIAF is 3.41 USD. The price decreased by -20.51% in the last trading session.


What is the ticker symbol for BIOAFFINITY TECHNOLOGIES INC stock?

The exchange symbol of BIOAFFINITY TECHNOLOGIES INC is BIAF and it is listed on the Nasdaq exchange.


On which exchange is BIAF stock listed?

BIAF stock is listed on the Nasdaq exchange.


What is BIOAFFINITY TECHNOLOGIES INC worth?

BIOAFFINITY TECHNOLOGIES INC (BIAF) has a market capitalization of 97.08M USD. This makes BIAF a Micro Cap stock.


How many employees does BIOAFFINITY TECHNOLOGIES INC have?

BIOAFFINITY TECHNOLOGIES INC (BIAF) currently has 57 employees.


Is BIOAFFINITY TECHNOLOGIES INC (BIAF) expected to grow?

The Revenue of BIOAFFINITY TECHNOLOGIES INC (BIAF) is expected to decline by -36.4% in the next year. Check the estimates tab for more information on the BIAF EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIOAFFINITY TECHNOLOGIES INC (BIAF) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIOAFFINITY TECHNOLOGIES INC (BIAF) stock pay dividends?

BIAF does not pay a dividend.


When does BIOAFFINITY TECHNOLOGIES INC (BIAF) report earnings?

BIOAFFINITY TECHNOLOGIES INC (BIAF) will report earnings on 2025-11-12.


What is the Price/Earnings (PE) ratio of BIOAFFINITY TECHNOLOGIES INC (BIAF)?

BIOAFFINITY TECHNOLOGIES INC (BIAF) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).


What is the Short Interest ratio of BIOAFFINITY TECHNOLOGIES INC (BIAF) stock?

The outstanding short interest for BIOAFFINITY TECHNOLOGIES INC (BIAF) is 4.62% of its float. Check the ownership tab for more information on the BIAF short interest.


BIAF Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BIAF Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to BIAF. BIAF may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BIAF Financial Highlights

Over the last trailing twelve months BIAF reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS increased by 22.58% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -246.03%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%10.53%
Sales Q2Q%-47.07%
EPS 1Y (TTM)22.58%
Revenue 1Y (TTM)4.97%

BIAF Forecast & Estimates

For the next year, analysts expect an EPS growth of 51.22% and a revenue growth -36.4% for BIAF


Analysts
Analysts43.33
Price TargetN/A
EPS Next Y51.22%
Revenue Next Year-36.4%

BIAF Ownership

Ownership
Inst Owners1.75%
Ins Owners16.79%
Short Float %4.62%
Short Ratio0.21